Simvastatin disrupts cytoskeleton and decreases cardiac fibroblast adhesion, migration and viability
Artículo
Open/ Download
Publication date
2012Metadata
Show full item record
Cómo citar
Copaja, Miguel
Cómo citar
Simvastatin disrupts cytoskeleton and decreases cardiac fibroblast adhesion, migration and viability
Author
Abstract
Statins reduce the isoprenoids farnesyl and geranylgeranyl pyrophosphate, essential intermediates,
which control a diversity of cellular events such as cytoskeleton integrity, adhesion, migration and viability.
Cardiac fibroblasts are the major non-myocyte cell constituent in the normal heart, and play a
key role in the maintenance of extracellular matrix. The effects of simvastatin on cardiac fibroblast processes
previously mentioned remain unknown. Our aims were to investigate the effects of simvastatin on
cytoskeleton structure and focal adhesion complex assembly and their relationships with cell adhesion,
migration and viability in cultured cardiac fibroblasts. To this end, cells were treated with simvastatin
for 24 h and changes in actin cytoskeleton, levels of vimentin and paxillin as well as their subcellular
localization were analyzed by Western blot and immunocytochemistry, respectively. Cell adhesion
to plastic or collagen coated dishes, migration in Transwell chambers, and cell viability were analyzed
after simvastatin treatment. Our results show that simvastatin disrupts actin cytoskeleton and focal
adhesion complex evaluated by phalloidin stain and immunocytochemistry for paxillin and vinculin. All
these effects occurred by a cholesterol synthesis-independent mechanism. Simvastatin decreased cell
adhesion, migration and viability in a concentration-dependent manner. Finally, simvastatin decreased
angiotensin II-induced phospho-paxillin levels and cell adhesion. We concluded that simvastatin disrupts
cytoskeleton integrity and focal adhesion complex assembly in cultured cardiac fibroblasts by a
cholesterol-independent mechanism and consequently decreases cell migration, adhesion and viability.
Patrocinador
This work was supported by Comisión Nacional de Ciencia y
Tecnología (CONICYT)-Chile [FONDECYT 1061059 to G.D.-A and
FONDAP 15010006 to S.L., G.D.A., M.C. and L.G.] and Fondo Mejoramiento
de la Calidad de la Educación Superior (MECESUP)
UCHO802. MC, PA, RV, IO, and MC hold Ph.D. fellowship from CONICYT,
Chile.
Quote Item
Toxicology 294 (2012) 42– 49
Collections